Business Context and Reporting Period
This Form 6-K filing by InflaRx N.V. covers the period ending November 10, 2025. The report incorporates by reference a press release announcing positive topline data from the Phase 2a basket study of INF904, an orally administered small-molecule C5aR inhibitor. The study evaluated safety, pharmacokinetics, and pharmacodynamics in patients with Hidradenitis Suppurativa (HS) and Chronic Spontaneous Urticaria (CSU).
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and does not contain a financial statement or management discussion of financial condition.
Material Changes and Clinical Results
The primary material update is the announcement of Phase 2a topline results for INF904:
- Hidradenitis Suppurativa (HS): Efficacy data reported for 29 of 31 patients. Patients demonstrated rapid reductions in abscesses and nodule (AN) counts and draining tunnel (dT) counts. Improvements in pain (NRS30), quality of life (DLQI), and HiSCR were observed at the end of treatment and deepened four weeks post-treatment. No serious adverse events were reported.
- Chronic Spontaneous Urticaria (CSU): Efficacy data reported for 30 of 31 patients. The 60 mg dosing cohort achieved the highest reduction in Urticaria Activity Score over 7 days (UAS7) with a change from baseline of -13.7 points at week 4. In severe CSU patients, the 60 mg dose reduced UAS7 by 15.4 points. Efficacy appeared equal in patients with high and low IgE levels. No serious adverse events were reported.
- Safety: Across all doses in both indications, no serious adverse events or safety signals were reported.
Guidance, Outlook, and Risks
Outlook and Data Status: The reported data are preliminary and subject to final review. Two HS patients and one CSU patient were excluded from the current analysis as they were still completing treatment. Management does not expect pending data to materially change overall efficacy trends, particularly as the most pronounced HS efficacy was observed in the 120 mg group, which is unaffected by the exclusions.
Comparative Limitations: The Company has not conducted head-to-head trials against third-party drugs. Comparisons to approved therapies are based on published data from different protocols and populations; therefore, direct comparative claims cannot be made.
Risks: The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to known and unknown risks. Investors are cautioned not to place undue reliance on these statements.
Investor Verification Checklist
- Verify the final dataset once the remaining patients complete treatment to confirm efficacy trends.
- Review the full clinical study report for detailed safety data beyond the "no serious adverse events" summary.
- Assess the limitations of the comparative data against approved HS and CSU therapies, noting the lack of head-to-head trials.
- Monitor subsequent filings for updates on the Phase 2b/3 development plan and regulatory strategy.
- Check the Company's cash runway in separate financial filings, as this 6-K does not disclose liquidity status.